FAIR VALUE - Narrative (Details)	1 Months Ended	3 Months Ended
	May 31, 2020 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Short-term contingent consideration		$ 24,458,000		$ 26,300,000
Long-term contingent consideration		26,600,000		22,200,000
Fair value of contingent consideration		9,167,000	$ 1,645,000
Level 2
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Convertible Debt, Fair Value Disclosures		69,400,000		92,500,000
Fair Value Of Convertible Notes, Par Value		$ 40,000,000		70,000,000
Revenue volatility
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.40
Discounted Cash Flow | Discount rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.085
Discounted Cash Flow | Credit spread
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.042
Zyla Life Sciences
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, royalty percentage	20.00%
INDOCIN
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration		$ 51,100,000		48,500,000
Short-term contingent consideration		24,500,000		26,300,000
Long-term contingent consideration		$ 26,600,000		$ 22,200,000
INDOCIN | Zyla Life Sciences | Iroko
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000,000